Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

JAMA oncology - 1 Aug 2015

Antonarakis Emmanuel S, Lu Changxue, Luber Brandon, Wang Hao, Chen Yan, Nakazawa Mary, Nadal Rosa, Paller Channing J, Denmeade Samuel R, Carducci Michael A, Eisenberger Mario A, Luo Jun

Abstract excerpt

IMPORTANCE: We previously showed that detection of androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer (CRPC) was associated with primary resistance to enzalutamide and abiraterone therapy, but the relevance of AR-V7 status in the context of chemotherapy is unknown. OBJECTIVE: To investigate whether AR-V7-positive patients would retain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Academic Medical Centers
Share to Androstenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Baltimore

Share to Docetaxel

Share to Kallikreins

Share to Neoplastic Cells, Circulating

Share to Prostatic Neoplasms, Castration-Resistant

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 26181238
DOI: 10.1001/jamaoncol.2015.1341
PMCID: PMC4537351

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.PMID 26181238Read ↗

Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review.Semantic proximity Read ↗

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.Semantic proximity Read ↗

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerSemantic proximity Read ↗

Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Semantic proximity Read ↗

[AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer].Semantic proximity Read ↗

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.Semantic proximity Read ↗

<scp>Androgen receptor</scp> splice variant 7 in castration‐resistant prostate cancer: Clinical considerationsSemantic proximity Read ↗

Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancerSemantic proximity Read ↗

An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells.Semantic proximity Read ↗

Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.Semantic proximity Read ↗

The Clinicopathological Characteristics of Androgen Receptor Splicing Variant 7 (AR-V7) Expression in Patients with Castration Resistance Prostate Cancer: A Systematic Review and Meta‐AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.